Navigation Links
Terminal in Medical Technology

Pivotal Clinical Data Published for the Only Laser Phototherapy Device Cleared by the FDA for Hair Growth

... exhibited significantly greater increase in mean terminal hair density than that seen in subjects treated ... that is healthy and capable of producing thick terminal hair. The enhanced environment in turn ... hair loss and stimulates the re-growth of thicker terminal hair. The HairMax LaserComb utilizes a ...

Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs

... (EPO) linked to Modigene's carboxyl terminal peptide (CTP) technology significantly increased ... on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in humans, ... Erythropoietin by Fusing the Carboxyl- terminal Peptide of Human Chorionic Gonadotropin b-Subunit ...

New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers

... (IST) has launched a clinical trial to test its breakthrough treatment for terminal blood cancers. IST has genetically engineered an antibody drug that ... IST's CEO, Mr. Alan Liddle, said multiple myeloma is a very debilitating terminal disease, with an estimated patient population of over 100,000 worldwide. ...

First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting

... Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(R) (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ... with Eculizumab in CAD A poster titled "Long-term Efficacy of the terminal Complement Inhibitor Eculizumab in a Patient with Cold Agglutinin Disease" ...

Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP

... by researchers at Washington University in St. Louis and is based on a short amino acid sequence that occurs naturally in humans, the carboxyl terminal peptide (CTP). When attached to a therapeutic protein, CTP extends the time that the protein is active in the body. The potential utility of the ...

Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH

... today at the 50th Annual Meeting of the American Society of Hematology in San Francisco in a poster session titled, "Safety and Efficacy of the terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results." The study was ...

GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.

... wall of the intestine and in regional lymph nodes. After an incubation period of several years, extensive granulomatous inflammation occurs in the terminal small intestine, leading to malabsorption and protein-losing enteropathy. Cattle shed minimal amounts of M. paratuberculosis in their feces during ...

Modigene Awarded Israeli Government Grant to Support Development of Its Longer-Acting Interferon Beta

... Modigene's technology was discovered by researchers at Washington University in St. Louis and is based on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in humans and when attached to a therapeutic protein, extends the time that the protein is active in the body. ...

eRT Announces the Availability of the Suicidality Monitoring System(TM) For Clinical Trials

... and research on computer interviewing, described some of the benefits of SMS: "SMS provides a user-friendly telephone interface as a computer terminal to collect sensitive suicidality data directly from trial subjects. Advantages of Interactive Voice Response (IVR) technology are: constant ...

Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies

... of lupus-prone mice. The mice in the R788 groups orally received 10 mg/kg, 20 mg/kg or 40 mg/kg twice a day, for 240 days. Baseline, periodic and terminal measurements of renal enzymes and proteinuria (presence of proteins in the urine associated with kidney malfunctions), blood urea nitrogen, and other ...

Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial

... dose could not be defined despite achieving high concentrations in blood. APD791 was rapidly absorbed and exposures were generally related to dose. terminal half-life (t1/2) of the parent plus active metabolites was also related to dose, and was approximately 11 hours at the higher doses. Dose dependent ...

DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug

... increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-beta-hydroxylase enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-alpha-demethylase, a ...

FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function

... be significant in the treatment of cardiovascular disease." Adult heart muscle cells lack the ability to regenerate following injury because of terminal differentiation. The number of heart cells is determined at birth and once damaged cannot repair themselves. Furthermore, many congenital ...

Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models

... and their bacterial loads determined by plating bone homogenates. The pharmacokinetic study of TT99000647 revealed a Cmax at 303 mcg/g of bone and a terminal half-life of 131 hours in bone. In the efficacy study, treatments resulted in the following proportion of sterilized tibia: 14% (untreated controls); ...

Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC

... or decreased during RDEA806 dosing. The systemic exposure of RDEA806 increased linearly from 50 mg to 600 mg under fasted or fed conditions. The terminal half-life of RDEA806 was up to 11 hours after single doses and up to 13 hours following multiple doses. With doses of 300 mg to 500 mg twice daily, ...

Studies Show Efficacy and Safety of Alexion's Soliris in Broad Population of PNH Patients

... in Vienna. These presentations included: "The terminal Complement Inhibitor Eculizumab Reduces ... (Abstract No. 0380) "Safety and Efficacy of the terminal Complement Inhibitor Eculizumab in Patients with ... when a duty arises under law. 1 Hillmen P. The terminal Complement Inhibitor Eculizumab Reduces ...

Aeolus Pharmaceuticals Announces Successful Completion of Multiple Dose Safety Study of AEOL 10150

... AEOL 10150 2 mg/kg/day resulted in lower, but sustained, plasma levels of approximately 1,500 ng/ml. Steady state occurred within three days and the terminal half-life was approximately 8 to 9 hours. Fifty-five percent of the dose was excreted in the urine as unchanged AEOL 10150. The maximum tolerated ...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

... 4,000 ng/mL to 15,000 ng/mL) were present as early as 20 minutes after administration -- Peramivir exhibited a long terminal half-life (17.7 to 24.3 hours) -- The bioavailability of single doses of i.m. peramivir is high (>98%) -- Peramivir was well-tolerated in ...

Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin

... technology was discovered by researchers at Washington University in St. Louis, Missouri, and is based on a short amino acid sequence, the Carboxyl terminal Peptide (CTP). CTP occurs naturally in the human body, and when attached to a therapeutic protein, extends the time that such protein can ...

DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein

... 2 diabetes. It is a single enantiomer of racemic ketoconazole which suppresses cortisol production by inhibiting the 11 beta hydroxylase enzyme, the terminal step in the adrenal synthesis of cortisol. This novel mechanism of action makes DIO-902 a first-in-category cortisol inhibitor. "Our unique ...

Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes

... subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Elimination ...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

... subjects, approximately 100% of the administered radioactivity was eliminated in feces (13%) or urine (87%) within one week of dosing. The apparent terminal t1/2 following a 100 mg oral dose of sitagliptin was approximately 12.4 hours and renal clearance was approximately 350 mL/min. Elimination ...
Other Contents
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... pandemic risk from strains of influenza virus increases with ... to become complacent that the most substantial threats have ... Influenza pandemics arise when a new virus strain – ... – spreads in the human population. There have been ... worst of which – the 1918 Spanish Flu – ...
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
(Date:10/22/2014)... 22, 2014 Best Cheap Hosting USA ... world. The site has recently announced that iPower ( ... for people from around the world. , “iPower is ... today and is providing various kinds of useful products ... insists on offering excellent customer service and a number ...
(Date:10/22/2014)... 2014 Losing Weight Your Body’s Way , ... you in the face, it certainly can be difficult to ... body an extra favor by doing it the healthy way? ... Instead, listen to your body, exercise regularly, and choose foods ... to losing weight; you need to exercise more and eat ...
(Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... are only about half as likely as white women to ... indicates, and the racial disparity persists even when donor eggs ... white patients became pregnant after IVF, compared to about 17 ... cycles over two years to tease out the impact of ...
Breaking Medicine News(10 mins):Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
Other TagsOther Tags